XTL Biopharmaceuticals (NASDAQ:XTLB) vs. Akebia Therapeutics (NASDAQ:AKBA) Financial Review

Akebia Therapeutics (NASDAQ:AKBA) and XTL Biopharmaceuticals (NASDAQ:XTLB) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, dividends, earnings, institutional ownership and profitability.

Institutional & Insider Ownership

33.9% of Akebia Therapeutics shares are owned by institutional investors. Comparatively, 4.4% of XTL Biopharmaceuticals shares are owned by institutional investors. 4.3% of Akebia Therapeutics shares are owned by company insiders. Comparatively, 29.0% of XTL Biopharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Akebia Therapeutics and XTL Biopharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Akebia Therapeutics	-13.54%	-88.88%	-7.74%
XTL Biopharmaceuticals	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent recommendations for Akebia Therapeutics and XTL Biopharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akebia Therapeutics	1	2	4	0	2.43
XTL Biopharmaceuticals	1	0	0	0	1.00

Akebia Therapeutics presently has a consensus target price of $3.90, indicating a potential upside of 335.51%. Given Akebia Therapeutics’ stronger consensus rating and higher possible upside, equities analysts plainly believe Akebia Therapeutics is more favorable than XTL Biopharmaceuticals.

Valuation & Earnings

This table compares Akebia Therapeutics and XTL Biopharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akebia Therapeutics	$236.20 million	1.05	-$5.34 million	($0.11)	-8.14
XTL Biopharmaceuticals	$450,000.00	12.77	-$6.97 million	($0.64)	-3.79

Akebia Therapeutics has higher revenue and earnings than XTL Biopharmaceuticals. Akebia Therapeutics is trading at a lower price-to-earnings ratio than XTL Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Akebia Therapeutics has a beta of 0.19, suggesting that its stock price is 81% less volatile than the S&P 500. Comparatively, XTL Biopharmaceuticals has a beta of 1.38, suggesting that its stock price is 38% more volatile than the S&P 500.

About Akebia Therapeutics

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company’s product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

About XTL Biopharmaceuticals

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.